See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Amgen's Five Prime Takeover Delivers Gastric Cancer Win

Summary by Pharmaphorum
Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal

2 Articles

PharmaphorumPharmaphorum
Center

Amgen's Five Prime takeover delivers gastric cancer win

Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal

Read Full Article
endpoints.newsendpoints.news

Amgen’s stomach cancer drug boosts survival in Phase 3, but ocular side effects leave questions

Amgen’s antibody candidate has cleared a late-stage trial in certain stomach cancer patients, but some side effects were more problematic than expected based on previous study results.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Monday, June 30, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Amgen icon

Amgen

News
For You
SearchBlindspotLocal